Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Acquired drug resistance leads to cancer recurrence, especially in metastatic melanoma with BRAF V600E mutations.
• Targeted therapies like dabrafenib can be overcome by drug-tolerant and resistant melanoma cells.

Purpose of the Study:

• Investigate cyclic membrane-active peptides as a therapeutic strategy against drug-resistant melanoma.
• Compare the efficacy of cyclic peptides (cTI, cGm) with dabrafenib in killing melanoma cells.

Main Methods:

• Utilized two cyclic peptides (cTI, cGm) with known anti-melanoma properties.
• Assessed peptide efficacy against melanoma cells sensitive, tolerant, and resistant to dabrafenib.
• Conducted lipidomic and proteomic analyses to study resistance mechanisms.
• Performed in vivo studies in mice to evaluate combination therapy.

Main Results:

• Cyclic peptides cTI and cGm rapidly kill metastatic melanoma cells, including drug-resistant ones.
• Melanoma cells did not develop resistance to long-term cTI treatment.
• Combination therapy of cTI and dabrafenib reduced metastases and improved survival in mice.

Conclusions:

• Cyclic membrane-active peptides are effective against drug-tolerant and resistant melanoma.
• cTI demonstrates potential as a therapeutic agent that circumvents acquired drug resistance.
• These peptides serve as valuable templates for developing new anticancer strategies.